Cediranib
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Explore 75 assets in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02530034CT.gov Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT03330821CT.gov Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03009240CT.gov Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02642965CT.gov Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02323607CT.gov Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | — | Completed | — | — | — |
NCT02528877CT.gov Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | — | Withdrawn | — | — | — |
NCT02381548CT.gov Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02299518CT.gov Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02093403CT.gov Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01885689CT.gov Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
Show 20 more trialsShow fewer
NCT01798901CT.gov AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01861314CT.gov Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT01823198CT.gov Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | — | Completed | — | — | — |
NCT01300572CT.gov Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | — | Completed | — | — | — |
NCT01231919CT.gov MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | — | Completed | — | — | — |
NCT01233921CT.gov Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | — | Completed | — | — | — |
NCT01139970CT.gov Veliparib and Temozolomide in Treating Patients With Acute Leukemia | — | Completed | — | — | — |
NCT01130506CT.gov Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01132586CT.gov Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00988715CT.gov Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00795002CT.gov Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00475150CT.gov Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00459212CT.gov GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT00357305CT.gov Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | — | Completed | — | — | — |
NCT00331513CT.gov Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00301938CT.gov 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00098826CT.gov SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00039117CT.gov Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00025415CT.gov Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | — | Completed | — | — | — |
NCT00016016CT.gov Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | M.D. Anderson Cancer Center | P3 | BB · 66 |
| Nivestim | City of Hope Medical Center | P2/3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cytarabine | National Cancer Institute (NCI) | P3 | BBB |
| Idarubicin | Fred Hutchinson Cancer Center | P2/3 | BB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| Mitoxantrone | Institut de Recherches Internationales Servier | P2 | BB |
+42 more in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-therapy-related-acute-myeloid-leukemia-and-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →